ClinicalTrials.gg
CompletedNCT06411730Updated Nov 12, 2024

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity

A Phase 1 interventional study of BMS-986368 in Healthy Participants, sponsored by Celgene. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-12.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2024, 2 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, tolerability, and drug levels of orally administered BMS-986368 in healthy participants, healthy elderly participants, and healthy participants of japanese ethnicity.

02

Conditions studied

  • Healthy Participants

Keywords

  • Pharmacokinetics
  • Pharmacodynamics
  • BMS-986368
  • CC-97489
  • Healthy Volunteers
  • Elderly Volunteers
  • Japanese Volunteers
  • Multiple Ascending Dose
  • Healthy Participants
  • Elderly Participants
  • Japanese Participants
03

In context

Lead sponsor

Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.

Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.

First submitted after Celgene became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be healthy male or non-pregnant and non-nursing female individuals.
  • For Part 2 only, participants must be of Japanese ethnicity (both biological parents are ethnically Japanese).
  • Participants must have a (BMI) of 18.0 kg/m2 to 33.0 kg/m2, inclusive.
  • Participants must have normal renal function at screening.

Exclusion criteria

Exclusion Criteria

  • Participants must not have a personal or first-degree family (individual's parents, siblings, and children) history of psychiatric disorder, including, but not limited to, schizophrenia, psychosis, bipolar disorder, panic disorder, generalized anxiety disorder, and obsessive-compulsive disorder.
  • Participants must not have any significant acute or chronic neurological illness (eg, history of intracranial or intraspinal hemorrhage, CNS lesions, recent bacterial or fungal meningitis, etc) as determined by the investigator.
  • Participants must not have a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, peripheral vascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary (GU) abnormalities/diseases including but not limited to peptic ulcer disease, or significant GI bleeding, pancreatitis, hypokalemia.
  • Participants must not have had a SARS-CoV-2 infection within 2 weeks prior to screening.
  • Participants must not have a history of any significant drug allergy or (such as anaphylaxis or hepatotoxicity).
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Cohort 1A

    Drug: BMS-986368

  • Experimental
    Cohort 1B

    Drug: BMS-986368

  • Experimental
    Cohort 1C

    Drug: BMS-986368

  • Experimental
    Cohort 2A

    Drug: BMS-986368

  • Experimental
    Cohort 2B

    Drug: BMS-986368

  • Experimental
    Cohort 2C

    Drug: BMS-986368

  • Experimental
    Cohort 2D

    Drug: BMS-986368

  • Experimental
    Cohort 3A

    Drug: BMS-986368

  • Experimental
    Cohort 3B

    Drug: BMS-986368

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 44 days

  2. Number of participants with serious adverse events (SAEs)

    Time frame: Up to 44 days

  3. Number of participants with vital sign (VS) abnormalities

    Time frame: Up to 21 days

  4. Number of participants with physical examination abnormalities

    Time frame: Up to 21 days

  5. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to 21 days

  6. Number of participants with clinical laboratory asssement abnormalities

    Time frame: Up to 21 days

  7. Number of participants with treatment-emergent suicidal ideation and behavior through assessment of Columbia Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to 21 days

Secondary outcomes

  1. Area under the plasma concentration-time curve (AUC)

    Time frame: Up to 16 days

  2. Maximum observed plasma concentration (Cmax)

    Time frame: Up to 16 days

  3. Time of maximum observed plasma concentration (Tmax)

    Time frame: Up to 16 days

  4. Absolute levels of monoacylglycerol lipase (MGLL) enzymatic activities in peripheral blood mononuclear cells (PBMCs)

    Time frame: Up to 21 days

  5. Percent change from baseline for monoacylglycerol lipase (MGLL) enzymatic activities in peripheral blood mononuclear cells (PBMCs)

    Time frame: Up to 21 days

  6. Plasma concentrations of anandamide (AEA)

    Time frame: Up to 21 days

  7. Percent change from baseline of anandamide (AEA)

    Time frame: Up to 21 days

  8. Whole blood concentrations of 2-arachidonoylglycerol (2-AG)

    Time frame: Up to 21 days

  9. Percent change from baseline of 2-arachidonoylglycerol (2-AG)

    Time frame: Up to 21 days

07

Study locations

1 site
  • Local Institution - 0001
    Anaheim, California 92780, United States
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Oct 2024, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2024
First posted
May 13, 2024
StartActual
May 31, 2024
Primary completionActual
Oct 28, 2024
CompletionActual
Oct 28, 2024
Last update
Nov 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06411730
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
May 13, 2024
Start date
May 31, 2024
Primary completion
Oct 28, 2024
Completion
Oct 28, 2024
Last update
Nov 12, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Irafamdastat

Start the discussion